Renal denervation: Analysis highlights 'confounding' factors in Medtronic's Symplicity-3 trial

An analysis of Medtronic's failed Symplicity-3 renal denervation trial highlights several 'confounding' factors that may have contributed to a missed efficacy endpoint, suggesting a way forward for more RDN studies.

European Heart Journal, Medtronic

News Well, Clinical Trials, Hypertension

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1z6lPi8